# Vasa (Justicia adhatoda)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/vasa
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-30
**Evidence Score:** 2 / 10
**Category:** Ayurveda
**Also Known As:** Justicia adhatoda, Adhatoda vasica, Malabar nut, Adulsa, Arusa, Bansa, Vasaka, Adhatoda, Justicia vasica, Vasa leaf, Indian hemp nettle

## Overview

Vasa (Justicia adhatoda) is an Ayurvedic herb whose primary bioactive alkaloid, vasicine, acts as a bronchodilator and expectorant by relaxing bronchial smooth muscle and stimulating mucociliary clearance. Its anti-inflammatory effects are driven by vasicine and vasicinone inhibiting [pro-inflammatory cytokine](/ingredients/condition/inflammation)s and COX-2 pathways, making it a clinically studied herb for respiratory conditions.

## Health Benefits

• Respiratory symptom relief: Highly significant reduction (P<0.001) in dyspnea, cough, and chest discomfort in Ayurvedic trials of 21-28 days
• COVID-19 recovery support: Reduced hypoxia markers (HIF-1α, ferritin, VEGF) and inflammation in RCT with 136 completers
• [Anti-inflammatory](/ingredients/condition/inflammation) effects: Inhibits IL-17A, IL-6, and other inflammatory cytokines through HIF-1α pathway modulation
• Asthma management: Traditional use supported by preclinical evidence showing bronchodilation and expectoration benefits
• Hypoxia reduction: Restores PHD2 expression and [mitochondrial function](/ingredients/condition/energy) in bronchial cells per mechanistic studies

## Mechanism of Action

Vasicine, the primary quinazoline alkaloid in Justicia adhatoda, stimulates beta-2 adrenergic receptors and inhibits phosphodiesterase, resulting in bronchial smooth [muscle relaxation](/ingredients/condition/sleep) and improved airflow. Vasicinone, its oxidized derivative, inhibits COX-2 and suppresses NF-κB signaling to reduce prostaglandin E2 and [pro-inflammatory cytokine](/ingredients/condition/inflammation) production including IL-6 and TNF-α. In the context of hypoxic inflammation, leaf extracts have demonstrated downregulation of HIF-1α, VEGF, and ferritin, suggesting modulation of the hypoxia-inducible pathway relevant to severe respiratory infections.

## Clinical Summary

Ayurvedic randomized controlled trials of 21–28 days duration have reported highly significant reductions (P<0.001) in dyspnea, cough, and chest discomfort using standardized Vasa formulations, though many of these studies are small and conducted primarily in Indian clinical settings. A notable RCT with 136 completers evaluating Vasa as adjunct therapy in COVID-19 recovery demonstrated measurable reductions in hypoxia markers including HIF-1α, ferritin, and VEGF compared to standard care alone. Evidence is predominantly from Ayurvedic polyherbal trials rather than isolated vasicine studies, limiting direct dose-response conclusions. Overall, the evidence is promising but requires larger, blinded, multicenter trials to establish standardized efficacy benchmarks.

## Nutritional Profile

Vasa (Justicia adhatoda) is not consumed as a food/nutrient source but as a medicinal herb; therefore, standard macronutrient profiling (carbohydrates, fats, protein) is not clinically relevant. Its therapeutic value derives from its bioactive phytochemical constituents:

**Primary Alkaloids:**
• Vasicine (peganine): ~0.5–1.5% w/w in dried leaf tissue; a quinazoline alkaloid responsible for bronchodilatory and mucolytic activity. Bioavailability is moderate via oral administration; hepatic [metabolism](/ingredients/condition/weight-management) converts a portion to vasicinone.
• Vasicinone: ~0.1–0.5% w/w; an oxidation product of vasicine with complementary bronchodilatory and respiratory smooth-muscle relaxant properties. Often present both endogenously and formed in vivo.
• Vasicol and vasicinol: Minor alkaloids (~0.01–0.1%) contributing to overall pharmacological synergy.
• Deoxyvasicine: Trace amounts; exhibits uterotonic and [antimicrobial](/ingredients/condition/immune-support) properties.

**Flavonoids & Phenolic Compounds:**
• Apigenin, kaempferol, and quercetin glycosides: Present in leaf extracts at variable concentrations (~0.2–0.8 mg/g dry weight collectively); contribute to [antioxidant](/ingredients/condition/antioxidant) and [anti-inflammatory](/ingredients/condition/inflammation) effects.
• Total phenolic content: Approximately 15–45 mg gallic acid equivalents (GAE)/g in ethanolic leaf extracts.
• Total flavonoid content: Approximately 8–20 mg quercetin equivalents/g in ethanolic extracts.

**Essential Oils & Terpenoids:**
• Minor volatile oil content (~0.02–0.05%); includes traces of sesquiterpenes and monoterpenes.
• Betaine and stachydrine have been reported in some analyses.

**Other Bioactive Compounds:**
• Saponins: Present in moderate quantities in root and leaf.
• Tannins: ~1–3% w/w in dried leaves; may affect bioavailability of co-administered compounds.
• Sterols: β-sitosterol detected in leaf and stem extracts.
• Vitamin C (ascorbic acid): Reported in fresh leaves at approximately 50–130 mg/100 g fresh weight (variable by growing conditions).

**Minerals (from leaf tissue analysis):**
• Potassium: ~1.0–1.8% dry weight
• Calcium: ~0.8–1.5% dry weight
• Iron: ~150–400 ppm
• Magnesium: ~0.3–0.6% dry weight
• Zinc, manganese, copper: Trace levels (10–50 ppm range)

**Fiber & Other Macronutrients (per 100 g dried leaf, approximate):**
• Crude fiber: ~12–18 g
• Crude protein: ~10–15 g
• Ash content: ~10–14 g
• Moisture (fresh leaf): ~70–80%

**Bioavailability Notes:**
• Vasicine shows reasonable oral bioavailability in animal models; peak plasma levels reached within 1–2 hours. Traditional preparation methods (kwatha/decoction, swarasa/fresh juice) enhance aqueous alkaloid extraction.
• Tannin content may reduce bioavailability of alkaloids and minerals if consumed with protein-rich substances.
• Traditional Ayurvedic processing (with honey or ginger as anupana) is believed to enhance mucosal absorption and reduce gastric irritation.
• Most clinical trials use standardized aqueous or hydroalcoholic extracts titrated to vasicine content (typically standardized to ≥0.5% vasicine alkaloids).

## Dosage & Preparation

Clinically studied doses include Vasa Ghan at 500mg daily for 14 days (COVID-19 trial) and traditional Ayurvedic formulations at 4-8g daily in divided doses for 21-28 days for respiratory conditions. No standardized extract doses have been established in human trials. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Vasa is generally considered safe at traditional doses (typically 3–6 g dried leaf or 10–20 mL fresh leaf juice daily) but high doses of vasicine have demonstrated uterotonic and abortifacient properties in animal studies, making it contraindicated during pregnancy. It may potentiate the effects of bronchodilator medications such as salbutamol or theophylline, and concurrent use warrants medical supervision to avoid additive hypotensive or bronchospastic effects. Rare adverse effects include gastrointestinal upset and mild nausea, particularly with concentrated extracts. No well-documented herb-drug interaction studies exist in humans, so caution is advised when combining with antihypertensive, anticoagulant, or immunosuppressant medications.

## Scientific Research

A randomized, open-label trial (n=136 COVID-19 patients) showed Vasa Ghan (500mg daily for 14 days) reduced hypoxia markers and [inflammation](/ingredients/condition/inflammation) without adverse effects (PMID: 38049897). Multiple Ayurvedic trials demonstrated highly significant relief (P<0.001) in respiratory symptoms using traditional formulations over 21-28 days, though these were open-label studies without specified sample sizes.

## Historical & Cultural Context

Vasa has been used in Ayurveda for over 2,000 years for respiratory ailments including asthma (Shwasa Roga) and cough (Kasa), traditionally prepared as decoctions, confections, or fermented liquids. The herb is promoted by India's Ministry of AYUSH for COVID-19 symptomatic management.

## Synergistic Combinations

Tinospora cordifolia, Tulsi (Holy Basil), Licorice root, Ginger, Turmeric

## Frequently Asked Questions

### What is vasicine and why is it important in Vasa?

Vasicine is a quinazoline alkaloid comprising approximately 0.5–1.5% of Justicia adhatoda leaf dry weight and is considered the primary active compound responsible for its bronchodilatory and expectorant effects. It relaxes bronchial smooth muscle by acting on beta-2 adrenergic receptors and inhibiting phosphodiesterase, and its oxidized form vasicinone contributes additional anti-inflammatory activity via COX-2 inhibition.

### How long does it take for Vasa to work for cough and breathing problems?

Clinical trials using Ayurvedic Vasa formulations have reported statistically significant reductions in cough frequency, dyspnea, and chest discomfort within 21 to 28 days of consistent use. Some practitioners report subjective symptomatic relief within the first week, particularly for productive cough, due to vasicine's mucolytic and expectorant actions, though robust rapid-onset data are lacking.

### Can Vasa be taken during pregnancy?

Vasa is contraindicated during pregnancy because vasicine has demonstrated uterotonic and abortifacient effects in animal models, stimulating uterine smooth muscle contractions. Traditional Ayurvedic texts also caution against its use in pregnancy, and until controlled human safety data are available, pregnant individuals should strictly avoid Vasa supplementation.

### Does Justicia adhatoda interact with any medications?

Vasa may produce additive bronchodilation when combined with beta-2 agonists like salbutamol or methylxanthines like theophylline, potentially increasing the risk of side effects such as tachycardia or hypotension. It has also shown preliminary antiplatelet activity in vitro, suggesting a possible interaction with anticoagulants such as warfarin, though human pharmacokinetic interaction studies have not been formally conducted.

### What is the typical dosage of Vasa (Justicia adhatoda) used in studies?

Traditional Ayurvedic dosing guidelines recommend 3–6 g of dried leaf powder or 10–20 mL of fresh leaf juice per day, typically divided into two or three doses. Clinical trials investigating respiratory outcomes have generally used standardized polyherbal formulations containing Vasa as a key ingredient rather than isolated vasicine, making exact vasicine dose equivalents difficult to specify from the published literature.

### What clinical evidence supports Vasa for respiratory conditions beyond cough?

Clinical trials demonstrate that Vasa significantly reduces dyspnea (shortness of breath) and chest discomfort within 21-28 days, with reductions achieving statistical significance (P<0.001) in Ayurvedic practice settings. An RCT with 136 participants showed Vasa reduces hypoxia markers including HIF-1α, ferritin, and VEGF, indicating benefits for oxygen utilization and inflammatory response in respiratory recovery. These findings suggest Vasa's utility extends to managing multiple respiratory symptoms rather than isolated cough relief.

### Who benefits most from Vasa supplementation for immune and respiratory support?

Individuals with chronic respiratory conditions like asthma, recurrent cough, or those recovering from respiratory infections—particularly those with inflammatory markers—appear to benefit most from Vasa supplementation. People experiencing hypoxia or elevated inflammatory cytokines (IL-6, IL-17A) may see particular benefit, as Vasa modulates the HIF-1α inflammatory pathway. Those seeking immune support during respiratory recovery periods represent another key population, though pregnant women and individuals on certain medications should consult healthcare providers first.

### How does Vasa reduce inflammation through the HIF-1α pathway?

Vasa inhibits key inflammatory cytokines including IL-17A, IL-6, and VEGF by modulating the hypoxia-inducible factor (HIF-1α) pathway, which regulates immune and inflammatory responses in respiratory tissues. This mechanism is particularly relevant in hypoxic conditions where HIF-1α becomes overactive, contributing to excessive inflammation and cellular stress. By normalizing HIF-1α signaling, Vasa addresses both inflammatory and oxygen-utilization problems simultaneously, making it relevant for conditions ranging from asthma to post-viral respiratory recovery.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*